AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31558454 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-level questions about latrine use or open defecation for every household member
Number of subjects: 2431
Study 31558454 — intervention group
Group type: COMPARATOR
Intervention: Household-level question used in India's DHS
Number of subjects: 2431
Study 31558454 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-level questions among households that received assistance to construct their latrines
Number of subjects: 2431
Study 31558454 — intervention group
Group type: COMPARATOR
Intervention: Household-level question among households that received assistance to construct their latrines
Number of subjects: 2431
Study 29066147 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg of methylprednisolone intravenously after anesthesia induction (n = 15)
Number of subjects: 45
Study 29066147 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg of methylprednisolone in cardiopulmonary bypass prime solution (n = 15)
Number of subjects: 45
Study 29066147 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 45
Study 25515800 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping strategies intervention (series of five interventions every 2 weeks)
Number of subjects: 57
Study 25515800 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical management (control group, telephoned every 2 weeks)
Number of subjects: 57
Study 24372225 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg every 2 weeks (Q2W)
Number of subjects: 98
Study 24372225 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Number of subjects: 98
Study 24372225 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 400 mg every 4 weeks
Number of subjects: 98
Study 23017533 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI)
Number of subjects: 280
Study 23017533 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based intervention (CBI)
Number of subjects: 280
Study 18706557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral hormone therapy (E(2) 1 mg plus drospirenone 2 mg/d for 2 months)
Number of subjects: 40
Study 18706557 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoral hormone therapy (3 mg/d 17beta intranasal E(2) and 200 mg/d vaginal micronized P for 14 days during two 28-day cycles)
Number of subjects: 40
Study 18706557 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 17127043 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (n-3 fatty acids 3.6 g/day)
Number of subjects: 162
Study 17127043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 16102378 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention with a consistent support person
Number of subjects: 127
Study 16102378 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 127
Study 16102378 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and usual care groups
Number of subjects: 127
Study 11984296 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 16
Study 11984296 — intervention group
Group type: COMPARATOR
Intervention: Sham‐training control (placebo)
Number of subjects: 16
Study 9859904 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer (2 mg/dose in 2.8 mL of 0.9% saline solution)
Number of subjects: 34
Study 9859904 — intervention group
Group type: COMPARATOR
Intervention: MDI-spacer (0.5 mg/dose)
Number of subjects: 34
Study 8567554 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia (inspired O2 fraction = 0.21)
Number of subjects: 9
Study 8567554 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia (inspired O2 fraction = 0.14)
Number of subjects: 9
Study 2225478 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone plus propylthiouracil (PTU, 100 mg orally every 8 h)
Number of subjects: 0
Study 2225478 — intervention group
Group type: COMPARATOR
Intervention: Propylthiouracil (PTU) alone
Number of subjects: 0
Study 472913 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PGE2 (5 mg total dose)
Number of subjects: 33
Study 472913 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal PGE2 (4-6 mg in gel form)
Number of subjects: 33
Study 472913 — intervention group
Group type: COMPARATOR
Intervention: Control group (unsuitable for induction)
Number of subjects: 33
Study 31232891 — intervention group
Group type: EXPERIMENTAL
Intervention: Short cephalomedullary nail (SN)
Number of subjects: 220
Study 31232891 — intervention group
Group type: COMPARATOR
Intervention: Long cephalomedullary nail (LN)
Number of subjects: 220
Study 28575048 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management program delivered via Facebook group
Number of subjects: 0
Study 28575048 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management program delivered via pamphlet
Number of subjects: 0
Study 28575048 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control Group)
Number of subjects: 0
Study 25434288 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD-CAM technology with surgical cutting guides and customised bone plates
Number of subjects: 10
Study 25434288 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with CAD-CAM technology)
Number of subjects: 10
Study 22621941 — intervention group
Group type: EXPERIMENTAL
Intervention: Active t-VNS (stimulation)
Number of subjects: 48
Study 22621941 — intervention group
Group type: COMPARATOR
Intervention: Sham t-VNS (no stimulation)
Number of subjects: 48
Study 21613038 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bottle adhesives with delayed composite placement
Number of subjects: 140
Study 21613038 — intervention group
Group type: EXPERIMENTAL
Intervention: Double application of single-bottle adhesives with delayed composite placement
Number of subjects: 140
Study 21613038 — intervention group
Group type: COMPARATOR
Intervention: Single application of single-bottle adhesives with immediate composite placement
Number of subjects: 140
Study 19336505 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Number of subjects: 39
Study 19336505 — intervention group
Group type: COMPARATOR
Intervention: Control (postmenopausal women without PHPT)
Number of subjects: 39
Study 16461091 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 months (Group 1)
Number of subjects: 84
Study 16461091 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil 45 minutes before coitus for 2 months (Group 2)
Number of subjects: 84
Study 16461091 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil 45 minutes before coitus plus topical EMLA cream applied 15 minutes before coitus for 2 months (Group 3)
Number of subjects: 84
Study 16461091 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical EMLA-cream-only for 2 months (Group 4)
Number of subjects: 84
Study 15306156 — intervention group
Group type: EXPERIMENTAL
Intervention: T/T genotype
Number of subjects: 159
Study 15306156 — intervention group
Group type: COMPARATOR
Intervention: C/C and C/T genotypes
Number of subjects: 159
Study 10072214 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon PTCA
Number of subjects: 48
Study 10072214 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion balloon PTCA
Number of subjects: 48
Study 8650033 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Mental State
Number of subjects: 335
Study 8650033 — intervention group
Group type: COMPARATOR
Intervention: DSWM III R criteria for dementing syndromes
Number of subjects: 335
Study 2370507 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet history interview
Number of subjects: 80
Study 2370507 — intervention group
Group type: COMPARATOR
Intervention: Self completed questionnaire
Number of subjects: 80
Study 6992382 — intervention group
Group type: EXPERIMENTAL
Intervention: dimetikon 0.2 g 4 times daily, 3 days before examination
Number of subjects: 200
Study 30683057 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated oxygen
Number of subjects: 35
Study 30683057 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 35
Study 27577730 — intervention group
Group type: EXPERIMENTAL
Intervention: Union group (patients with successful union)
Number of subjects: 48
Study 27577730 — intervention group
Group type: COMPARATOR
Intervention: Non-union group (patients without successful union)
Number of subjects: 48
Study 27577730 — intervention group
Group type: EXPERIMENTAL
Intervention: Union group
Number of subjects: 48
Study 27577730 — intervention group
Group type: COMPARATOR
Intervention: Non-union group
Number of subjects: 48
Study 27577730 — intervention group
Group type: EXPERIMENTAL
Intervention: DSVA > 5 cm
Number of subjects: 48
Study 27577730 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-LL > 30°
Number of subjects: 48
Study 24529619 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent headaches
Number of subjects: 872
Study 24529619 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraines
Number of subjects: 872
Study 24529619 — intervention group
Group type: COMPARATOR
Intervention: Silent cerebral infarction
Number of subjects: 872
Study 24529619 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication for headache prophylaxis
Number of subjects: 872
Study 22759328 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day concomitant therapy (rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily, metronidazole 400 mg three times a day, clarithromycin MR 1 g once daily)
Number of subjects: 110
Study 22759328 — intervention group
Group type: COMPARATOR
Intervention: 5-day concomitant therapy (rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily, metronidazole 400 mg three times a day, clarithromycin MR 1 g once daily)
Number of subjects: 110
Study 20451585 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsolateral prefrontal cortex stimulation at 2 or 4 V
Number of subjects: 5
Study 20451585 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 5
Study 17651267 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 40
Study 17651267 — intervention group
Group type: COMPARATOR
Intervention: Dissection tonsillectomy with bipolar diathermy haemostasis
Number of subjects: 40
Study 15520843 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 102
Study 15520843 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 102
Study 12008806 — intervention group
Group type: EXPERIMENTAL
Intervention: NiteWhite Excel 2Z
Number of subjects: 18
Study 12008806 — intervention group
Group type: EXPERIMENTAL
Intervention: Rembrandt Xtra‐Comfort
Number of subjects: 18
Study 12008806 — intervention group
Group type: COMPARATOR
Intervention: fx (Challenge Products)
Number of subjects: 18
Study 10435819 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 30
Study 10435819 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 30
Study 7676685 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg acetylsalicylic acid (Thrombo-ASS 50 mg)
Number of subjects: 0
Study 7676685 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg (marketed preparation)
Number of subjects: 0
Study 2151741 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids and/or cytotoxic drugs
Number of subjects: 196
Study 2151741 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 196
Study 6119780 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 10
Study 6119780 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 200 mg twice daily
Number of subjects: 10
Study 6119780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg t.d.s. and 400 mg at night
Number of subjects: 10
Study 6119780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30878990 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of plaster cast immobilisation
Number of subjects: 0
Study 30878990 — intervention group
Group type: COMPARATOR
Intervention: 6 weeks of plaster cast immobilisation
Number of subjects: 0
Study 28030983 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived Benefits Scale
Number of subjects: 1012
Study 28030983 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived Barriers Scale
Number of subjects: 1012
Study 28030983 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Enjoyment Scale
Number of subjects: 1012
Study 28030983 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MVPA and psychosocial benefits
Number of subjects: 1012
Study 28030983 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical benefits
Number of subjects: 1012
Study 25134024 — intervention group
Group type: EXPERIMENTAL
Intervention: Postquit environmental risk factors (cigarette availability)
Number of subjects: 0
Study 25134024 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to contextual risk factors during the prequit period
Number of subjects: 0
Study 25134024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression survival analyses on time spent in high-risk contexts postquit
Number of subjects: 0
Study 25134024 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline risk factors (gender, nicotine dependence, depressive symptoms, living with a smoker)
Number of subjects: 0
Study 24658473 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg parecoxib per day (group I)
Number of subjects: 20
Study 24658473 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%, group II)
Number of subjects: 20
Study 21068096 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (depomedrone)
Number of subjects: 77
Study 21068096 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 77
Study 21068096 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-animal stabilised hyaluronic acid (durolane)
Number of subjects: 77
Study 21068096 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no injection)
Number of subjects: 77
Study 19339358 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (dosage not specified)
Number of subjects: 2855
Study 17534686 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg intravenously every 2 weeks)
Number of subjects: 32
Study 17534686 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg intravenously every 2 weeks) plus low-dose interferon alfa-2b (1 MU/m2 subcutaneously daily)
Number of subjects: 32
Study 17534686 — intervention group
Group type: COMPARATOR
Intervention: Low-dose interferon alfa-2b (1 MU/m2 subcutaneously daily)
Number of subjects: 32
Study 17534686 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with or without low-dose interferon alfa-2b
Number of subjects: 32
Study 16701925 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 pfu Towne CMV vaccine with adjuvant recombinant interleukin-12 (rhIL-12)
Number of subjects: 0
Study 16701925 — intervention group
Group type: COMPARATOR
Intervention: 3000 pfu Towne CMV vaccine without adjuvant recombinant interleukin-12 (rhIL-12)
Number of subjects: 0
Study 15131557 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 200
Study 15131557 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 200
Study 11016321 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 70
Study 8795400 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentosan polysulphate sodium (PPS) 200 mg three times daily for 6 weeks
Number of subjects: 41
Study 8795400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 1825503 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg t.i.d. for 5-6 weeks)
Number of subjects: 12
Study 1825503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6336819 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (given intravenously on eight consecutive days)
Number of subjects: 42
Study 6336819 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone (control group)
Number of subjects: 42
Study 6336819 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (given subsequently to control patients)
Number of subjects: 42
Study 31455871 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat meal
Number of subjects: 16
Study 31455871 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 16
Study 31455871 — intervention group
Group type: COMPARATOR
Intervention: scAT (subcutaneous abdominal adipose tissue)
Number of subjects: 16
Study 31827657 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative PVB with PCIA (Group A)
Number of subjects: 44
Study 31827657 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative PVB with PCIA (Group B)
Number of subjects: 44
Study 31827657 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of preoperative and postoperative PVB (Group C)
Number of subjects: 44
Study 28625369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 36
Study 28625369 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 36
Study 28625369 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 36
Study 25428694 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent‐adolescent group‐administered (PA)
Number of subjects: 331
Study 25428694 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐administered with telephone support (SA)
Number of subjects: 331
Study 25428694 — intervention group
Group type: COMPARATOR
Intervention: No‐treatment control
Number of subjects: 331
Study 24366288 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg
Number of subjects: 199
Study 24366288 — intervention group
Group type: COMPARATOR
Intervention: rabeprazole 10 mg
Number of subjects: 199
Study 24366288 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg (CYP2C19 PM phenotype)
Number of subjects: 199
Study 24366288 — intervention group
Group type: COMPARATOR
Intervention: rabeprazole 10 mg (CYP2C19 PM phenotype)
Number of subjects: 199
Study 23078196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention
Number of subjects: 61
Study 23078196 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual control
Number of subjects: 61
Study 19237631 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials stopped early for positive results
Number of subjects: 27
Study 17533782 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine ophthalmic emulsion
Number of subjects: 0
Study 17533782 — intervention group
Group type: COMPARATOR
Intervention: Routine cataract extraction
Number of subjects: 0
Study 15206909 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine 2 mg (titrated up to 3 mg if necessary)
Number of subjects: 40
Study 15206909 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg (titrated up to 100 mg if necessary)
Number of subjects: 40
Study 11452249 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutamoren mesylate 0.8 mg/kg per day for 8 days (group III)
Number of subjects: 18
Study 9554633 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic peak flowmeter (with a 3-month memory)
Number of subjects: 26
Study 7802600 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (BDP)
Number of subjects: 24
Study 7802600 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (PSL)
Number of subjects: 24
Study 2839444 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative thoracic radiation with systemic chemotherapy (cytoxan, adriamycin, and platinum) for 6 months
Number of subjects: 164
Study 2839444 — intervention group
Group type: COMPARATOR
Intervention: Post-operative thoracic radiation without systemic chemotherapy
Number of subjects: 164
Study 2839444 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy group (radiation + chemotherapy)
Number of subjects: 164
Study 31733608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus memory support (CS + Memory Support; n = 22)
Number of subjects: 42
Study 31733608 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy as-usual (CT-as-usual; n = 20)
Number of subjects: 42
Study 31185995 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured personal diabetes care for 6 years
Number of subjects: 1381
Study 31185995 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 1381
Study 31185995 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured personal diabetes care
Number of subjects: 1381
Study 27559857 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience and Coping Intervention (RCI)
Number of subjects: 129
Study 27559857 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 129
Study 26353786 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen peptides (15 g/d)
Number of subjects: 53
Study 23896763 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-T MRI with bilateral transmit-receive coil and adiabatic inversion-based fat suppression (FS)
Number of subjects: 17
Study 23896763 — intervention group
Group type: COMPARATOR
Intervention: 3-T MRI
Number of subjects: 17
Study 23896763 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-T MRI
Number of subjects: 17
Study 21338535 — intervention group
Group type: EXPERIMENTAL
Intervention: HDP meal (hydroxypropyl-distarch phosphate)
Number of subjects: 10
Study 21338535 — intervention group
Group type: COMPARATOR
Intervention: Waxy maize starch meal
Number of subjects: 10
Study 19549022 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support advising against nine potentially inappropriate medications
Number of subjects: 63
Study 19549022 — intervention group
Group type: COMPARATOR
Intervention: Control group (no decision support)
Number of subjects: 63
Study 19549022 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support
Number of subjects: 63
Study 17634049 — intervention group
Group type: EXPERIMENTAL
Intervention: Xian-zhong injection
Number of subjects: 127
Study 17634049 — intervention group
Group type: COMPARATOR
Intervention: Sodium Hyaluronate injection
Number of subjects: 127
Study 15164445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreduction followed by hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 102